Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
Want to see TSHA full AI Analyst Report?
TSHA Stock Chart & Stats
$6.43
-$0.08(-4.26%)
At close: 4:00 PM EST
$6.43
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$2.25 - $7.30
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.51M
Market Cap
$1.84B
Enterprise Value$1.29B
Total Cash (Recent Filing)$276.58M
Total Debt (Recent Filing)$17.77M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding287,361,020
10 Day Avg. Volume3,072,988
30 Day Avg. Volume2,505,406
Financial Highlights & Ratios
PEG Ratio2.91
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue172.68
Enterprise Value/Gross Profit195.73
Enterprise Value/Ebitda-9.99
Forecast
1Y Price Target
$12.86Price Target Upside99.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA cash balance near $277M and very low debt-to-equity (~0.08) materially reduces near-term solvency risk and gives management flexibility to complete pivotal dosing, PPQ and early commercial planning without immediate financing. This durability underpins program execution over 2–3 years.
Regulatory Alignment And BLA Enabling WorkDocumented FDA alignment on an interim approval pathway and the start of commercial‑process PPQ materially de‑risk regulatory timing and demonstrate regulatory engagement. Successful PPQ execution would structurally improve probability and timeliness of a BLA submission.
Robust Early Efficacy And Tolerability SignalsConsistent high response rates across cohorts and an absence of treatment‑related SAEs support a favorable benefit-risk profile, increasing the likelihood regulators, clinicians and payers will accept trial endpoints and consider use of a minimally invasive intrathecal approach at launch.
Bears Say
Large Recurring Cash Burn And LossesSustained large operating losses and negative free cash flow mean the company will remain dependent on external financing if milestones slip or spend stays elevated. Continued burn erodes equity and can force dilutive raises or constrain investment in manufacturing redundancy and commercialization.
Manufacturing And Supply‑chain Execution RiskPPQ success and reliable commercial supply are critical to submission and launch. Reliance on a single primary partner and postponed redundancy planning creates a persistent operational vulnerability: delays or quality issues could push regulatory timelines and materially raise commercialization costs.
Minimal And Volatile Revenue BaseRevenue is negligible and declining while operating expenses ramp, meaning high gross margins are irrelevant to near‑term sustainability. Until a product is commercial, the business lacks recurring cash flows, increasing reliance on financing and exposing the company to dilution and execution risk.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $2.25 and its highest was $7.30 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $1.84B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on May 06, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.023.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 287,361,020 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went up 0.576%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.86 (99.96% Upside)
$12.86 (99.96% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 322.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.80%
12-Months-Change
Fundamentals
Return on Equity
-56.07%
Trailing 12-Months
Asset Growth
117.08%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
TSHA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical, preclinical and regulatory momentum for TSHA-102 — including FDA alignment on a potential expedited pathway, robust Part A efficacy signals (high response rates, multiple developmental milestones and functional gains), initiation of BLA-enabling PPQ, and a solid cash position with runway into 2028. These positives are tempered by materially higher R&D and G&A spending that drove a near-doubling of net loss year-over-year, ongoing uncertainty around whether the FDA will accept a 6-month interim for full approval versus requiring 12-month data, and the need to complete PPQ and validate manufacturing redundancy. Overall, the operational and scientific progress appears to outweigh the financial and timing risks at this stage.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$12.86
▲(99.96% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
3.33% Insiders
9.41% Mutual Funds
45.38% Other Institutional Investors
29.88% Public Companies and
Individual Investors